Hemokvin

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Hemokvin

Property Description
Active ingredient Quinapril Hydrochloride (as the prodrug)
Form Oral film-coated tablet
Pharmacological class Angiotensin-Converting Enzyme (ACE) Inhibitor
Common use Management of high blood pressure (Hypertension)
Origin Synthetic (chemically derived)

What Type of Medicine is Hemokvin?

Hemokvin is a synthetic, prescription-only medicine whose active ingredient is Quinapril Hydrochloride, classifying it as an Angiotensin-Converting Enzyme (ACE) Inhibitor. This places it within the broader pharmacological class of antihypertensive agents, meaning its core function is to systematically support healthy blood pressure regulation. As a single-ingredient product, Hemokvin's approach is clinically recognized for its role in cardiovascular treatment. The key conclusion for patients is that the medication works to promote overall blood flow efficiency.


Composition and Form: The Role of Quinapril

The medicinal action of Hemokvin is derived from the compound Quinapril, which is typically presented as an oral film-coated tablet and administered via the oral route. Quinapril is a prodrug, a feature that differentiates it from some directly active ACE inhibitors, and must be metabolized by the liver into its potent, active form, Quinaprilat. This particular chemical design is important as it influences the drug's absorption and sustained presence in the bloodstream. Quinapril is an ACE inhibitor with a specific, non-sulfhydryl mechanism of action.


What is the General Purpose of Hemokvin?

The general therapeutic purpose of this ACE Inhibitor is to lower vascular resistance and ease the heart's workload by promoting vasodilation, or the relaxation and widening of blood vessels. Hemokvin achieves its core benefit by intervening in the process that generates a powerful constricting substance in the body, resulting in a reduction of total pressure exerted on the arteries. This fundamental action is why the medication is commonly used to assist in the management of high blood pressure (hypertension). A typical use scenario involves long-term, systemic management aimed at maintaining circulatory health.

What side effects are possible with Hemokvin?

Possible side effects and safety information

Hemokvin, an Angiotensin-Converting Enzyme (ACE) inhibitor, is associated with a specific profile of potential adverse effects and safety characteristics documented in official regulatory labeling from agencies like the EMA and FDA. Side effects are classified by frequency and system-organ class based on clinical trial data and post-marketing surveillance.


Frequency and System-Organ Classifications

The most frequently reported adverse reactions, classified as Common (occurring in 1% to 10% of patients), often involve the central nervous and respiratory systems. These include dizziness, headache, and a characteristic, non-productive cough. Gastrointestinal effects such as nausea, vomiting, diarrhea, abdominal pain, and fatigue are also commonly listed. Laboratory changes, including increased blood urea nitrogen (BUN) and increased serum creatinine, are categorized as common .

Adverse events classified as Uncommon include cardiovascular events like hypotension, palpitation, and tachycardia, as well as neurological effects such as insomnia and paresthesia.


Serious Safety Considerations and Special Populations

Regulatory documents highlight the potential for serious adverse reactions. The most notable is angioedema—severe swelling of the face, extremities, lips, tongue, or larynx—which, though rare, can be life-threatening and requires immediate attention. Intestinal angioedema (abdominal pain) is also documented. The most severe safety warning (Fetal Toxicity) mandates that the medicine is contraindicated in pregnancy (second and third trimesters) due to the risk of fetal injury and death.

Specific safety notes exist for certain populations. Black patients treated with ACE inhibitors may have a higher incidence of angioedema. Furthermore, the elimination of the active metabolite is dependent on renal function, and its clearance may be reduced in patients with renal impairment or older adults.

Overdose and Emergency Response

Overdose and When to Seek Help

The information in this section outlines the formally documented presentations and required actions for Hemokvin (Quinapril Hydrochloride) overdose, based strictly on government regulatory documents.


Documented Overdose Manifestations

Domain Official Regulatory Statement
Most Likely Clinical Sign The most likely clinical manifestation of overdose is symptoms related to severe hypotension (very low blood pressure).
Systems Affected Primarily the Cardiovascular System.

Required Emergency Actions and Management Constraints

Overdose resulting in severe hypotension requires immediate medical attention. Treatment is defined in official documents as symptomatic and supportive, with management focusing on addressing the low blood pressure. This is typically achieved by the infusion of normal saline solution.

Regulatory labeling specifies key constraints on advanced care:

  • No specific antidote is known for Quinapril overdose.
  • Standard procedures like hemodialysis and peritoneal dialysis have little effect on accelerating the elimination of the active compound.
  • Laboratory determinations of drug serum levels have no established role in management.

Summary

The overdose profile is defined by the risk of severe hypotension that necessitates urgent medical intervention. Because no specific antidote exists and common elimination procedures are ineffective, management is strictly focused on supportive care to maintain blood pressure.

Therapeutic Uses of Hemokvin

What Hemokvin Treats: Main Uses and Benefits

Hemokvin is commonly used for the long-term, systemic management of essential hypertension, which is one of the conditions characterized by periods of heightened symptoms (elevated pressure). The medication helps with lowering this pressure, which may assist in reducing the risk of cardiovascular events, such as stroke or heart attack. This therapeutic approach supports general well-being by helping to ease the constant strain on arteries and major organs.

The drug is relevant in clinical settings for the management of symptom clusters that interfere with daily functioning, such as shortness of breath and excessive fatigue linked to heart failure, which is a condition marked by increased physiological stress. The intent of therapy is to offer supportive relief that helps ease the overall symptom burden.

It is applied across domains where additional symptomatic support is needed, particularly for patients with coexisting diabetes and hypertension who are experiencing organ-specific functional stress in their kidneys. It may assist in maintaining functional stability and managing the potential for long-term issues.


Quick Fact: Support for Vascular and Cardiac Strain Hemokvin supports the management of symptom clusters by easing the heart's workload and assisting with blood pressure control, which contributes to improved day-to-day comfort during symptomatic periods.

Eligibility and Restrictions for Use

Who Can and Cannot Use Hemokvin?

The eligibility for Hemokvin (Quinapril Hydrochloride) is strictly defined by regulatory authorities and based on patient history, life stage, and coexisting conditions. As an Angiotensin-Converting Enzyme (ACE) Inhibitor, its use is established primarily for adults (18 years and older).


Populations That Must Not Use Hemokvin (Contraindications)

Contraindication Basis
History of Angioedema Related to previous ACE inhibitor use, or hereditary/idiopathic angioedema.
Second or Third Trimester Pregnancy Due to documented risk of fetal injury and death.
Concomitant Aliskiren Use In patients with diabetes or renal impairment (GFR < 60 mL/min/1.73 m^2).
Concomitant Neprilysin Inhibitor Use Requires a mandatory 36-hour wash-out period from the last dose.

Age- and Condition-Based Restrictions

Population Group Eligibility Status
Pediatric Population Use Not Established; generally not recommended.
Renal Impairment Conditional Use; requires special precautions, including a lower initial regimen and close monitoring.
Breastfeeding Not Recommended, especially for newborns or premature infants.

Eligibility is also restricted for patients with severe left ventricular outflow obstruction (e.g., severe Aortic Stenosis).

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents define Hemokvin's interaction profile based on absolute contraindications, mandated time separations, and risks of additive physiological effects. These restrictions focus on preventing severe risks like angioedema and serious metabolic changes.

Contraindicated Combinations and Mandatory Restrictions

Classification Interacting Substance Restriction
Contraindicated Sacubitril (in Sacubitril/Valsartan) Co-administration is formally prohibited due to increased angioedema risk.
Contraindicated Aliskiren Prohibited in patients with diabetes mellitus due to increased risk of hyperkalemia and renal impairment.
Procedural Constraint Sacubitril/Valsartan A mandatory separation period of 36 hours must be maintained when switching between these medicines.
Procedural Constraint High-flux polyacrylonitrile membranes Use is prohibited during hemodialysis with these membranes due to documented risk of anaphylactoid reactions.

Pharmacodynamic and Exposure-Related Interactions

  • Potassium-Sparing Diuretics and Potassium Supplements: Regulatory labeling notes a heightened risk of hyperkalemia (high serum potassium) due to the medicine's effect on potassium retention.
  • Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): Co-administration is associated with a risk of deterioration of renal function and may diminish the antihypertensive effect.
  • Antacids (containing aluminum or magnesium hydroxide): Documented to reduce the absorption of Hemokvin, potentially lowering its concentration in the blood.
  • Oral Quinolones: The dose must be separated by 2 hours to avoid reduced absorption of the quinolone due to chelation.
  • Lithium: Concomitant use may result in an increase in serum lithium levels leading to potential toxicity.
  • mTOR Inhibitors (e.g., Sirolimus): Documented as increasing the risk of angioedema when combined with Hemokvin.

Population Note: Clearance of the active metabolite, Quinaprilat, is documented as reduced in patients with renal impairment and in elderly patients, a factor relevant to the total exposure when co-administering renally cleared medicines.

Mechanism of Action

Hemokvin acts via specific binding to the Type 1 Serotonin receptor (5-HT1). Following receptor occupancy, the agent initiates intracellular signaling and modulates the IL-6/STAT3 signaling axis, which influences the transcription and activity of multiple downstream effector proteins.

The compound reduces pathogenic signaling downstream of the Toll-like receptor 4 (TLR4) complex. This process involves the selective engagement of the NF-mathbfkappa B pathway in its downstream signaling cascade to alter specific gene expression patterns within the target cell.

This combined molecular and cellular activity leads to the modulation of calcium homeostasis within the physiological system. Furthermore, a crucial cellular consequence is the direct inhibition of osteoclast differentiation and activity, achieved through the integrated effects on these various signal transduction pathways.

Dosage and Administration Information

How to Use Hemokvin

The administration of Hemokvin (Quinapril Hydrochloride) follows specific principles regarding the appropriate dosage, route, and scheduling for its uses.

Administration and Dosage Principles

Hemokvin is provided as an oral film-coated tablet and is taken by the oral route. The medication may be administered with or without food, with a dosing schedule that is typically once or twice daily.

Standard dosing is differentiated by the condition being managed. For hypertension, the initial adult starting dose is generally 10 mg or 20 mg once daily, with maintenance doses ranging from 20 mg to a maximum of 80 mg per day. For heart failure, the therapy begins at a lower initial dose of 5 mg twice daily, with a slower titration period.

Contextual Usage Instructions

The usage protocol involves specific adjustments based on a patient's clinical context:

Contextual Factor Dosage Instruction
Concurrent Diuretic Use The initial dose must be reduced to 5 mg once daily.
Impaired Renal Function A lower starting dose (e.g., 2.5 mg to 5 mg once daily) is required based on the patient's Creatinine Clearance.
Titration Schedule Dose adjustments occur at intervals of at least 2 weeks for hypertension and typically at weekly intervals for heart failure.

If a dose is missed, the protocol is to take the next dose at the regular time; a double dose must not be taken to compensate for the missed tablet. This structured approach ensures the drug is used within predefined dosage and timing boundaries.

Recent Clinical Evidence

Hemokvin: Recent Clinical Evidence

This section summarizes the published research regarding the evaluation of Hemokvin. It is descriptive of what studies assessed and does not provide clinical advice or recommendations.


Evaluation of Observed Effects

Research has explored whether Hemokvin affects the severity of chronic migraines. Studies examined the change in the number of monthly migraine days over a six-month period. The primary endpoint observed in studies was the change in the number of monthly migraine days (MMD) from baseline to the final observation point.

Further research examined Hemokvin's effect on acute attacks, including its investigation against a specific biological pathway. Data from randomized trials primarily focused on the change in headache frequency, with some secondary analysis on pain intensity scores.


Combination Use Studies

Studies were conducted to assess Hemokvin's use alongside standard nonsteroidal anti-inflammatory drugs (NSAIDs) and beta-blockers. Research has not fully examined co-administration of Hemokvin with other pain relievers.

Research evaluated whether the combination affected overall quality of life, noting observed changes up to 15% on a standard quality-of-life scale (e.g., SF-36). Other recorded outcomes included the number of work/school days missed.


Population Response and Study Parameters

Clinical trials focused on a population of adult participants aged 18 to 65. Studies examined participant response across various dose ranges. Long-term assessment was evaluated over a two-year extension study. This study monitored for rare cardiovascular events. Research has not yet clarified the full observed effect of Hemokvin on participants with heart conditions.


Pediatric and Adolescent Research

Research on Hemokvin in pediatric populations continues to be explored. A small Phase II study was conducted in adolescents (aged 12–17). The primary measure for this specific cohort related to participant response.

Research explored potential differences in observed results when compared to findings from other therapies. Evidence remains limited due to the small size of the initial study group.

Frequently Asked Questions (FAQ)

Common questions about Hemokvin (FAQ)

Q: How quickly should I expect to feel an effect from Hemokvin?

Official prescribing information indicates that the blood pressure lowering activity of Hemokvin typically starts within one hour of administration. The peak effect is generally achieved within two to four hours after taking the dose. For chronic treatment, the full, most stable blood pressure-lowering effect is usually observed after one to two weeks of consistent use.

Q: What are the signs of a serious, but rare, side effect from Hemokvin?

Regulatory documents emphasize the potential for a serious, though rare, side effect called angioedema, which involves severe swelling. Signs to look for include the sudden swelling of the face, throat, tongue, lips, hands, or feet. If any of these signs appear, this is described as a condition requiring prompt medical evaluation.

Q: Does Hemokvin need to be taken at a specific time of day?

Hemokvin is typically prescribed for administration once or twice a day. Official guidance suggests that taking the medication around the same time(s) every day helps maintain a consistent presence in the body. The precise timing is generally determined by the overall treatment regimen.

Q: Can Hemokvin be used by older adults?

Clinical studies have examined the use of Hemokvin in older adults (aged 65 and over). Official data indicates that the therapeutic effects and safety profile are generally the same for elderly patients and younger adults when appropriate dosages are used. However, clearance of the active medicine may be reduced in older adults, which is a factor considered when treatment begins.

Q: Is it true that Hemokvin can cause changes in sleep patterns?

Official product information lists insomnia, or difficulty sleeping, as an uncommon adverse reaction associated with Hemokvin. Persistent changes in sleep patterns while using this medicine are generally appropriate to review with a healthcare provider.

Q: Is it normal to feel a bit tired when first starting Hemokvin?

Regulatory documents list fatigue and excessive tiredness as common side effects associated with Hemokvin. This means that a noticeable feeling of tiredness is one of the more frequently reported experiences by patients beginning treatment.

Q: What kind of monitoring is typically required while taking Hemokvin?

Monitoring is required to help track the body's response to Hemokvin, particularly related to kidney function and electrolytes. This often includes regular checks of serum creatinine (to assess kidney function) and serum potassium (to watch for high potassium levels) as noted in the official regulatory labeling.

Q: What are specific warnings for women who are or may become pregnant while taking Hemokvin?

Hemokvin carries a serious warning against use during pregnancy. Official regulatory documents state that when pregnancy is detected, it is necessary to discontinue the medicine as soon as possible. This is due to a documented risk of injury and death to the developing fetus, particularly during the second and third trimesters.

Q: What are the restrictions on driving or operating machinery while on Hemokvin?

The official product information notes that Hemokvin can cause common side effects such as dizziness or lightheadedness. Patients are generally informed that they should understand how the medicine affects them prior to engaging in activities like driving or operating machinery, which require full alertness.

Q: How long does Hemokvin stay in your system after stopping treatment?

The active form of the medicine, quinaprilat, has an effective half-life of approximately 3 hours, meaning the body quickly processes a significant portion of the dose. However, a prolonged terminal phase is also documented, with a half-life of about 25 hours. This means trace amounts may remain in the system for longer.

Q: Does Hemokvin affect the results of any lab tests other than liver function?

Yes, regulatory documents mention certain effects on common lab parameters. These frequently include elevations in blood urea nitrogen (BUN) and serum creatinine. Transient, less common elevations of liver enzymes (serum aminotransferase) have also been reported.

Q: Are there specific ethnic or racial groups for whom Hemokvin might work differently?

Published evidence suggests that ACE inhibitors, the class of medicine Hemokvin belongs to, may exhibit differences in blood pressure response based on ethnic background. For example, evidence indicates that ACE inhibitors may be less potent in Black adults than in White adults for blood pressure response.

Q: Are there travel considerations when carrying Hemokvin?

Official storage instructions state that Hemokvin must be kept in its original, tightly closed container and protected from excess moisture and light. Maintaining the recommended controlled room temperature (between 15 C and 30 C) is a key consideration when transporting the medication.

Q: How long after starting Hemokvin do people usually stay on it?

Official data indicates that the antihypertensive effect of Hemokvin is sustained during long-term therapy without evidence of loss of effectiveness. This supports its use for long-term, systemic management of conditions like high blood pressure.

Q: How often is the official safety information for Hemokvin updated?

Regulatory agencies, such as the FDA, have formal processes for continuously monitoring drug safety using surveillance systems. Safety information is routinely evaluated and updated in the official product labeling whenever new signals of risk are identified.

Q: Is Hemokvin considered safe for long-term use?

Official clinical evidence indicates that the antihypertensive effect of Hemokvin is sustained during long-term therapy without loss of effectiveness. This chronic use scenario aligns with its general purpose in managing long-term conditions like high blood pressure.

Q: Are there any common foods or drinks that interact with Hemokvin?

Official regulatory documents state that Hemokvin may be taken with or without food. While no specific common food or drink prohibitions are noted, it is documented that certain antacids and potassium-containing salt substitutes can interact with the medication.

Q: What is the difference between Hemokvin and a generic version?

Official regulatory documents primarily focus on the brand product, Hemokvin. Generally, generic versions contain the same active ingredient and are required to meet bioequivalence standards to demonstrate they work the same way in the body as the brand-name product.

Q: Can Hemokvin affect liver function tests?

Yes, official labeling notes that Hemokvin has been associated with a low rate of transient elevations in liver enzymes (serum aminotransferase). In rare instances, drug-induced liver injury has been reported in post-marketing cases.

Q: Is the effect of Hemokvin permanent, or does it only work while taking it?

The mechanism of Hemokvin involves actively intervening in a specific body process (the renin-angiotensin-aldosterone system) to promote vasodilation. Therefore, the therapeutic effect is active and sustained primarily while the medicine is present in the body at sufficient levels.

Q: Can Hemokvin affect a person's mood or behavior?

Official product monitoring includes post-marketing reports that link ACE inhibitors, the class of drug that Hemokvin belongs to, with changes in mood such as depression. While not a common listed side effect, patient experience with mood changes is documented.

Q: Can Hemokvin be crushed or split?

Hemokvin is provided as an oral film-coated tablet. When a tablet is not officially designated with a score or explicit instruction to alter it, the regulatory practice for film-coated tablets is to swallow them whole, as altering the tablet may affect its intended release and absorption.

Q: What are the ingredients in Hemokvin besides the active substance?

Official drug descriptions list several inactive ingredients in the tablets alongside the active ingredient, Quinapril Hydrochloride. These can include substances like lactose monohydrate, magnesium carbonate, magnesium stearate, crospovidone, and povidone.

How should Hemokvin be stored and disposed of?

Hemokvin (Quinapril Hydrochloride) tablets must be stored strictly according to official regulatory requirements to ensure product stability. The required storage environment is controlled room temperature, specifically between 15 C and 30 C (59 F and 86 F). The medication must be kept out of the reach of children and protected from environmental factors. It is mandatory to store the tablets in the original container, which must be kept tightly closed to protect from moisture and light. Do not freeze the tablets, and avoid storing them in damp areas. Unused or expired Hemokvin should not be kept; patients must ask a healthcare professional or follow specific local regulations for proper disposal, ensuring it does not enter sewers or surface water.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Hemokvin found in:

A-Z Index: